About Us

Our Commitment

As a portfolio company of Paragon Biosciences, Emalex is unceasing in its pursuit to improve the lives of people living with central nervous system (CNS) disorders through meaningful scientific breakthroughs.

Leadership

Our leadership team is comprised of remarkable professionals who are passionate about innovative solutions that improve the lives of people living with chronic central nervous system conditions.

Frederick Munschauer, M.D., MSc., FAAN
Chief Medical Officer, Neurology and
Senior Vice President, Medical and
Scientific Affairs

Tim Rudolphi
Chief Commercial Officer

Paul Reinfelds, J.D., Ph.D.
Senior Vice President of Legal Affairs and General Counsel

Jenny Swalec
Vice President, Regulatory Affairs and Quality Assurance

Doug Frandsen
Corporate Controller

Jay White, Ph.D.
Vice President, Chemistry, Manufacturing and Controls (CMC)

Sarah Atkinson, M.D.
Vice President, Clinical Development

George Karkanias, Ph.D., MBA, MSc.
Vice President, Global Head of Medical and Scientific Affairs

Trish Rice
Vice President, Biostatistics and Data Management

Jose (Jesse) Zapata
Associate Vice President, Quality Assurance

David Kim
Senior Director, Clinical Operations

Meredith M. Miller
Senior Director, Clinical Operations

Joy Schleyer
Senior Director, Clinical Operations

Christine H. Soulje, Ph.D.
Senior Director, Product Development

Tom Stothoff
Senior Director, Chemistry, Manufacturing and Controls (CMC) Regulatory Affairs

Emalex Founder and Chairman

Jeff Aronin
Paragon Founder, Chairman and CEO